Key clinical point: Reduction in the frequency of convulsive seizures is significantly associated with improvements in executive function in patients with Dravet syndrome.
Major finding: The median reduction in convulsive seizure frequency in patients with Dravet syndrome receiving fenfluramine was 71%.
Study details: A 1-year open-label extension of a phase 3 study of adjunctive fenfluramine in patients with Dravet syndrome.
Disclosures: Zogenix, the company that is developing fenfluramine as a treatment for Dravet syndrome, funded the study. Several investigators are employees of Zogenix.
Bishop KI et al. AES 2019, Abstract 2.438.